AMC6156 0.1mg
DrugOral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
NCT Number: NCT07072195
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Interested in participating?
Request Info65 year and older
All sexes
Interventional
Phase 2
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
Time frame: At Visit 1 (Screening), Visit 2 (Week 0, Baseline), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Time frame: At Visit 1 (Screening), Visit 2 (Week 0, Baseline), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Time frame: At Visit 2 (Week 0), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Time frame: At Visit 1 (Screening) and Visit 5 (Week 12)
Time frame: At Visit 1 (Screening), Visit 2 (Week 0) ,Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)
Time frame: At Visit 2 (Week 0) and Visit 5 (Week 12)
Time frame: At Visit 2 (Week 0) and Visit 5 (Week 12)
Contact information is provided by the study sponsor or research team.
Animuscure Inc.
Industry
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07575958
Atrophy, Muscular Atrophy
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06853275
Age-associated Muscle Loss, Atrophy
Omaha, Nebraska, United States
View Trial DetailsNCT06689618
Aging, Atrophy
Columbia, Missouri, United States
View Trial DetailsNCT06988176
Atrophy, Elderly (People Aged 65 or More)
Chapel Hill, North Carolina, United States
View Trial Details